Bank of New York Mellon’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-132,343
| Closed | -$13.5M | – | 4429 |
|
|
2023
Q2 | $13.5M | Buy |
132,343
+30,668
| +30% | +$2.9M | ﹤0.01% | 1784 |
|
|
2023
Q1 | $9.24M | Sell |
101,675
-277
| -0.3% | -$16.3K | ﹤0.01% | 1972 |
|
|
2022
Q4 | $3.87M | Buy |
101,952
+2,573
| +3% | +$88.5K | ﹤0.01% | 2488 |
|
|
2022
Q3 | $2.5M | Buy |
99,379
+7,071
| +8% | +$196K | ﹤0.01% | 2697 |
|
|
2022
Q2 | $2.81M | Sell |
92,308
-28,367
| -24% | -$846K | ﹤0.01% | 2643 |
|
|
2022
Q1 | $3.95M | Buy |
120,675
+1,927
| +2% | +$57.2K | ﹤0.01% | 2550 |
|
|
2021
Q4 | $3.13M | Sell |
118,748
-6,420
| -5% | -$497K | ﹤0.01% | 2727 |
|
|
2021
Q3 | $12.6M | Buy |
125,168
+5,999
| +5% | +$703K | ﹤0.01% | 1998 |
|
|
2021
Q2 | $16.9M | Buy |
119,169
+24,079
| +25% | +$2.72M | ﹤0.01% | 1830 |
|
|
2021
Q1 | $9.48M | Sell |
95,090
-1,296
| -1% | -$151K | ﹤0.01% | 2112 |
|
|
2020
Q4 | $11.9M | Buy |
96,386
+2,806
| +3% | +$369K | ﹤0.01% | 1916 |
|
|
2020
Q3 | $9.12M | Sell |
93,580
-4,708
| -5% | -$588K | ﹤0.01% | 1899 |
|
|
2020
Q2 | $15.3M | Sell |
98,288
-20,526
| -17% | -$3.12M | ﹤0.01% | 1605 |
|
|
2020
Q1 | $17.1M | Sell |
118,814
-4,868
| -4% | -$940K | 0.01% | 1389 |
|
|
2019
Q4 | $25.3M | Buy |
123,682
+17,878
| +17% | +$3.26M | 0.01% | 1435 |
|
|
2019
Q3 | $8.49M | Sell |
105,804
-7,735
| -7% | -$656K | ﹤0.01% | 2011 |
|
|
2019
Q2 | $10.7M | Buy |
113,539
+9,755
| +9% | +$842K | ﹤0.01% | 1929 |
|
|
2019
Q1 | $8.87M | Buy |
103,784
+13,782
| +15% | +$1.14M | ﹤0.01% | 2030 |
|
|
2018
Q4 | $5.05M | Sell |
90,002
-4,879
| -5% | -$298K | ﹤0.01% | 2284 |
|
|
2018
Q3 | $7.76M | Buy |
94,881
+29,294
| +45% | +$2.06M | ﹤0.01% | 2175 |
|
|
2018
Q2 | $2.29M | Buy |
65,587
+16,473
| +34% | +$502K | ﹤0.01% | 2781 |
|
|
2018
Q1 | $1.01M | Buy |
49,114
+1,950
| +4% | +$50.2K | ﹤0.01% | 3216 |
|
|
2017
Q4 | $1.34M | Buy |
47,164
+2,461
| +6% | +$68.7K | ﹤0.01% | 3078 |
|
|
2017
Q3 | $1.39M | Buy |
44,703
+10,744
| +32% | +$323K | ﹤0.01% | 3028 |
|
|
2017
Q2 | $1.07M | Buy |
33,959
+11,746
| +53% | +$289K | ﹤0.01% | 3207 |
|
|
2017
Q1 | $503K | Buy |
22,213
+3,407
| +18% | +$84.2K | ﹤0.01% | 3556 |
|
|
2016
Q4 | $411K | Buy |
18,806
+3,236
| +21% | +$81.8K | ﹤0.01% | 3672 |
|
|
2016
Q3 | $410K | Buy |
15,570
+4,599
| +42% | +$91.3K | ﹤0.01% | 3628 |
|
|
2016
Q2 | $217K | Buy |
+10,971
| New | +$213K | ﹤0.01% | 3872 |
|
Other funds holding RETA
Bank of New York Mellon's RETA Position: Q3 2023 in Review
Bank of New York Mellon sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 132,343 shares — an estimated $13.5M sold.
Bank of New York Mellon first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $25.3M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Bank of New York Mellon reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Bank of New York Mellon sold 132,343 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $13.5M.
- Bank of New York Mellon first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Bank of New York Mellon's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $25.3M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.